Membranous nephropathy: from models to man
- PMID: 24892704
- PMCID: PMC4089468
- DOI: 10.1172/JCI72270
Membranous nephropathy: from models to man
Abstract
As recently as 2002, most cases of primary membranous nephropathy (MN), a relatively common cause of nephrotic syndrome in adults, were considered idiopathic. We now recognize that MN is an organ-specific autoimmune disease in which circulating autoantibodies bind to an intrinsic antigen on glomerular podocytes and form deposits of immune complexes in situ in the glomerular capillary walls. Here we define the clinical and pathological features of MN and describe the experimental models that enabled the discovery of the major target antigen, the M-type phospholipase A2 receptor 1 (PLA2R). We review the pathophysiology of experimental MN and compare and contrast it with the human disease. We discuss the diagnostic value of serological testing for anti-PLA2R and tissue staining for the redistributed antigen, and their utility for differentiating between primary and secondary MN, and between recurrent MN after kidney transplant and de novo MN. We end with consideration of how knowledge of the antigen might direct future therapeutic strategies.
Figures
Similar articles
-
Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.Nefrologia. 2014 May 21;34(3):353-9. doi: 10.3265/Nefrologia.pre2013.Dec.12291. Epub 2014 Feb 10. Nefrologia. 2014. PMID: 24798555 English, Spanish.
-
Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy.Clin Exp Nephrol. 2017 Feb;21(1):117-126. doi: 10.1007/s10157-016-1235-2. Epub 2016 Feb 1. Clin Exp Nephrol. 2017. PMID: 26830547 Free PMC article.
-
Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A2 receptor antibody-positive idiopathic membranous nephropathy: a case report.BMC Nephrol. 2020 Oct 12;21(1):431. doi: 10.1186/s12882-020-02086-z. BMC Nephrol. 2020. PMID: 33046023 Free PMC article.
-
Membranous Nephropathy: A Journey From Bench to Bedside.Am J Kidney Dis. 2016 Jul;68(1):138-47. doi: 10.1053/j.ajkd.2016.01.030. Epub 2016 Apr 13. Am J Kidney Dis. 2016. PMID: 27085376 Free PMC article. Review.
-
[Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].Rev Med Brux. 2015 May-Jun;36(3):166-71. Rev Med Brux. 2015. PMID: 26372979 Review. French.
Cited by
-
Large B-cell Lymphoma-Associated Membranous Nephropathy With Positive PLA2R on Kidney Biopsy.Cureus. 2023 Nov 16;15(11):e48902. doi: 10.7759/cureus.48902. eCollection 2023 Nov. Cureus. 2023. PMID: 38106713 Free PMC article.
-
Identification of biomarkers related to immune and inflammation in membranous nephropathy: comprehensive bioinformatic analysis and validation.Front Immunol. 2023 Oct 9;14:1252347. doi: 10.3389/fimmu.2023.1252347. eCollection 2023. Front Immunol. 2023. PMID: 37876929 Free PMC article.
-
Knowledge Translation in Glomerulonephritis: Successes in Translational Research From the Bench to Bedside.Can J Kidney Health Dis. 2023 Aug 23;10:20543581231191839. doi: 10.1177/20543581231191839. eCollection 2023. Can J Kidney Health Dis. 2023. PMID: 37637870 Free PMC article. Review.
-
Clinical covariates influencing clinical outcomes in primary membranous nephropathy.BMC Nephrol. 2023 Aug 10;24(1):235. doi: 10.1186/s12882-023-03288-x. BMC Nephrol. 2023. PMID: 37563703 Free PMC article.
-
Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis.Arch Med Sci. 2020 Oct 14;19(2):411-419. doi: 10.5114/aoms.2020.99899. eCollection 2023. Arch Med Sci. 2020. PMID: 37034519 Free PMC article. Review.
References
-
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2(2):139–274. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
